Intravenous BPC-157 was well tolerated in a first pilot study

A very small pilot, in two healthy adults, found no adverse effects or changes in organ markers.

Most evidence on BPC-157 comes from animal studies, where it has been investigated in tendon, muscle and mucosal repair. This pilot sought a first safety signal in people: two healthy adults received intravenous infusions of up to 20 mg.

There were no adverse effects and no measurable changes in heart, liver, kidney, thyroid or glucose markers. With only two participants it is a first step: larger, controlled trials are needed.

In three points

Human pilot with only two participants
No adverse effects or marker changes
Most efficacy evidence is still from animals

Compounds mentioned

BPC-157

Original source: Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
PubMed · Alternative Therapies in Health and Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.